Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from NovaBay Pharma ( (NBY) ).
On March 12, 2026, NovaBay Pharmaceuticals amended and restated its certificate of incorporation in Delaware, removing a ban on stockholder action by written consent, adding limited officer exculpation provisions, and raising its authorized common stock to 5 billion shares. These governance and capital changes, approved by the board and stockholders, significantly expand NovaBay’s flexibility for future financings and corporate actions.
At the March 12, 2026 special meeting, stockholders also approved issuing shares underlying pre-funded warrants from private placements in January 2026 and October 2025, adopted a 2026 Equity Incentive Plan, and confirmed charter changes aligning with Delaware corporate law. Collectively, these approvals cement prior financing arrangements, broaden the share pool for strategic and compensation purposes, and may reshape the company’s ownership structure and governance dynamics.
The most recent analyst rating on (NBY) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.
Spark’s Take on NBY Stock
According to Spark, TipRanks’ AI Analyst, NBY is a Neutral.
The score is primarily held down by weak financial performance (shrinking revenue, very large operating losses, and heavy cash burn). Technicals add near-term weakness with the stock below key short-term moving averages and low momentum readings. Valuation is difficult to assess favorably due to a negative P/E and no dividend, while recent financing-related corporate events raise dilution and strategic risk despite improving access to capital.
To see Spark’s full report on NBY stock, click here.
More about NovaBay Pharma
NovaBay Pharmaceuticals, Inc. is a specialty pharmaceutical company operating in the healthcare sector. It focuses on developing and commercializing medical products, with its capital structure centered on common stock issued to support financing activities and equity-based incentive plans for employees and other stakeholders.
Average Trading Volume: 519,987
Technical Sentiment Signal: Strong Sell
Current Market Cap: $33.18M
Learn more about NBY stock on TipRanks’ Stock Analysis page.